Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06195709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Study acronym: ECLECTIC
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 27, 2028 to Sep 27, 2029
    • Study sites: 13 to 21
    • Study completion date: Sep 27, 2029 to Sep 27, 2030
    v8
  2. Site contacts updated at 1 of 13 sites
    • Eligibility criteria expanded, about 2 words
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Study sites: 8 to 13v5
  5. Start date: Apr 17, 2024 to May 27, 2024
    • Primary completion date: Aug 15, 2028 to Sep 27, 2028
    • Study completion date: Aug 15, 2029 to Sep 27, 2029
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 15, 2024 to Apr 17, 2024
    • Site details revised at 8 of 8 sites
    v3
  2. Secondary endpoints: details revised at 5 of 10 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.
Trial Details
NCT Number NCT06195709
Lead Sponsor Institut Curie
Collaborators: Zionexa
Conditions
(from sponsor)		 Breast Carcinoma
Related terms Breast Neoplasms, Neoplasm Metastasis
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov